AIM ImmunoTech, Inc.
(NYSE Amex Equities : AIM)

( )
AIM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. -1.54%74.761.0%$1946.65m
AMGNAmgen, Inc. -2.76%202.731.3%$903.34m
REGNRegeneron Pharmaceuticals, Inc. 3.23%488.292.6%$833.80m
BIIBBiogen, Inc. 0.08%316.381.5%$759.21m
VRTXVertex Pharmaceuticals, Inc. 2.60%237.951.9%$588.30m
MRNAModerna, Inc. -1.74%29.950.0%$535.64m
ILMNIllumina, Inc. -1.13%273.123.5%$472.24m
ALXNAlexion Pharmaceuticals, Inc. 2.90%89.792.0%$286.04m
AAgilent Technologies, Inc. -1.50%71.581.6%$228.47m
EXASEXACT Sciences Corp. -0.74%58.0021.0%$194.38m
INCYIncyte Corp. 1.47%73.232.5%$176.59m
SGENSeattle Genetics, Inc. 0.08%115.386.1%$169.50m
BMRNBioMarin Pharmaceutical, Inc. 2.44%84.504.3%$166.37m
NVAXNovavax, Inc. -5.04%13.58114.7%$124.83m
ALNYAlnylam Pharmaceuticals, Inc. 0.02%108.858.7%$102.43m

Company Profile

AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.